Dickson Bbuye
Kampala, C, Uganda
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial.
Journal: Open forum infectious diseases
Published: January 26, 2026
Efavirenz metabolism and CNS toxicity in Ugandan children: impact of CYP2B6 genotype and plasma metabolite profiles.
Journal: Frontiers in pharmacology
Published: December 30, 2025
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial.
Journal: The Lancet. Child & adolescent health
Published: August 28, 2025
Correction: Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers.
Journal: AIDS research and therapy
Published: September 02, 2024
Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers.
Journal: AIDS research and therapy
Published: June 10, 2024
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study.
Journal: British journal of clinical pharmacology
Published: January 20, 2024
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Journal: The Lancet. Child & adolescent health
Published: March 06, 2023
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial.
Journal: Journal of the International AIDS Society
Published: November 13, 2022
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Journal: The lancet. HIV
Published: March 28, 2022
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Journal: The New England journal of medicine
Published: December 29, 2021
Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-naïve Ugandan children.
Journal: Acta paediatrica (Oslo, Norway : 1992)
Published: December 26, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026